Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV

Epstein‐Barr virus (EBV) is the cause of infectious mononucleosis and is associated with a variety of life‐threatening diseases in humans. Therefore the development of an effective vaccine is an important objective. Many of the initial studies of vaccine efficacy analyse the ability of vaccine preparations to prevent the induction of lymphomas in cottontop tamarins by the B95‐8 strain of EBV. We used a vaccinia virus recombinant expressing gp340, vMA1, tested previously in the cotton‐top tamarin, to evaluate a common marmoset model in which the challenge virus, M81, resembles more closely the wild‐type strains of EBV in the general population than does the standard B95‐8 strain. We characterised the M81 strain of EBV with respect to the sequence of its gp340/220 gene and in regard to the presence of a region deleted in B95‐8. Replication of the challenge virus in the group vaccinated with vMA1 was decreased when compared to control groups. © 1996 Wiley‐Liss, Inc.